Hims & Hers CEO Andrew Dudum responded to a Federal Trade Commission lawsuit filed earlier in the month, arguing that regulators have misunderstood the company’s operational model. Speaking in a Tuesday interview, Dudum stated that the allegations reflect confusion about how the company is transforming healthcare through digital innovation. He suggested the FTC had worked with the company over many years but ultimately pursued litigation seeking publicity rather than substantive resolution.
The FTC, Los Angeles County, and Utah filed suit against Hims & Hers in July, alleging the company improperly shared user health information with advertisers including Meta and Snap, charged for prescriptions before patients consulted healthcare providers, and created barriers to subscription cancellation. Dudum characterized the company as an active disruptor in healthcare and maintained that its business practices prioritize expanding patient access to care and treatment.
Dudum also addressed the company’s transition regarding GLP-1 medications used for weight loss and obesity treatment. When these drugs faced shortages, Hims & Hers legally produced and sold discounted compounded versions. Following supply stabilization, Novo Nordisk pursued patent infringement litigation, but the Danish pharmaceutical manufacturer withdrew its suit in March, with the telehealth company agreeing to sell Novo’s branded medications through its platform.
Dudum argued that offering compounded GLP-1 drugs at lower prices demonstrated the viability of affordability and pressured the market toward lower prices. He predicted that cash-paying patients could eventually access these medications for $40 to $50 monthly, down from the current $150 to $200 range. The CEO emphasized the company’s commitment to leveraging artificial intelligence in healthcare transformation, noting plans to develop proprietary AI systems and move away from third-party solutions, positioning proprietary healthcare data as the company’s most valuable asset.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI